nodes	percent_of_prediction	percent_of_DWPC	metapath
Buprenorphine—ABCG2—Riluzole—amyotrophic lateral sclerosis	0.505	0.708	CbGbCtD
Buprenorphine—CYP1A2—Riluzole—amyotrophic lateral sclerosis	0.208	0.292	CbGbCtD
Buprenorphine—Biliary colic—Riluzole—amyotrophic lateral sclerosis	0.0114	0.0443	CcSEcCtD
Buprenorphine—Hypoventilation—Riluzole—amyotrophic lateral sclerosis	0.00744	0.029	CcSEcCtD
Buprenorphine—CNS depression NOS—Riluzole—amyotrophic lateral sclerosis	0.00676	0.0264	CcSEcCtD
Buprenorphine—Hypoxia—Riluzole—amyotrophic lateral sclerosis	0.00436	0.017	CcSEcCtD
Buprenorphine—Respiratory distress—Riluzole—amyotrophic lateral sclerosis	0.00436	0.017	CcSEcCtD
Buprenorphine—Upset stomach—Riluzole—amyotrophic lateral sclerosis	0.00423	0.0165	CcSEcCtD
Buprenorphine—Hyperventilation—Riluzole—amyotrophic lateral sclerosis	0.00403	0.0157	CcSEcCtD
Buprenorphine—Depersonalisation—Riluzole—amyotrophic lateral sclerosis	0.00395	0.0154	CcSEcCtD
Buprenorphine—Cyanosis—Riluzole—amyotrophic lateral sclerosis	0.00392	0.0153	CcSEcCtD
Buprenorphine—Ileus—Riluzole—amyotrophic lateral sclerosis	0.00392	0.0153	CcSEcCtD
Buprenorphine—Apathy—Riluzole—amyotrophic lateral sclerosis	0.00388	0.0151	CcSEcCtD
Buprenorphine—Flat affect—Riluzole—amyotrophic lateral sclerosis	0.00385	0.015	CcSEcCtD
Buprenorphine—Respiratory depression—Riluzole—amyotrophic lateral sclerosis	0.00368	0.0144	CcSEcCtD
Buprenorphine—Pulmonary function test decreased—Riluzole—amyotrophic lateral sclerosis	0.00368	0.0144	CcSEcCtD
Buprenorphine—Amblyopia—Riluzole—amyotrophic lateral sclerosis	0.00359	0.014	CcSEcCtD
Buprenorphine—Abscess—Riluzole—amyotrophic lateral sclerosis	0.0035	0.0137	CcSEcCtD
Buprenorphine—Apnoea—Riluzole—amyotrophic lateral sclerosis	0.00327	0.0128	CcSEcCtD
Buprenorphine—Accidental injury—Riluzole—amyotrophic lateral sclerosis	0.00313	0.0122	CcSEcCtD
Buprenorphine—Dysarthria—Riluzole—amyotrophic lateral sclerosis	0.00293	0.0114	CcSEcCtD
Buprenorphine—Gait disturbance—Riluzole—amyotrophic lateral sclerosis	0.00284	0.0111	CcSEcCtD
Buprenorphine—Coordination abnormal—Riluzole—amyotrophic lateral sclerosis	0.00282	0.011	CcSEcCtD
Buprenorphine—Respiratory failure—Riluzole—amyotrophic lateral sclerosis	0.00282	0.011	CcSEcCtD
Buprenorphine—Neck pain—Riluzole—amyotrophic lateral sclerosis	0.00281	0.0109	CcSEcCtD
Buprenorphine—Hiccups—Riluzole—amyotrophic lateral sclerosis	0.00277	0.0108	CcSEcCtD
Buprenorphine—Injection site reaction—Riluzole—amyotrophic lateral sclerosis	0.00276	0.0108	CcSEcCtD
Buprenorphine—Dermatitis contact—Riluzole—amyotrophic lateral sclerosis	0.00274	0.0107	CcSEcCtD
Buprenorphine—Urinary incontinence—Riluzole—amyotrophic lateral sclerosis	0.00268	0.0104	CcSEcCtD
Buprenorphine—Depressed level of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00268	0.0104	CcSEcCtD
Buprenorphine—Coma—Riluzole—amyotrophic lateral sclerosis	0.00253	0.00989	CcSEcCtD
Buprenorphine—Mental disability—Riluzole—amyotrophic lateral sclerosis	0.00241	0.00939	CcSEcCtD
Buprenorphine—Euphoric mood—Riluzole—amyotrophic lateral sclerosis	0.00238	0.0093	CcSEcCtD
Buprenorphine—Ear pain—Riluzole—amyotrophic lateral sclerosis	0.00236	0.0092	CcSEcCtD
Buprenorphine—Injury—Riluzole—amyotrophic lateral sclerosis	0.00219	0.00854	CcSEcCtD
Buprenorphine—Libido decreased—Riluzole—amyotrophic lateral sclerosis	0.00217	0.00847	CcSEcCtD
Buprenorphine—Diplopia—Riluzole—amyotrophic lateral sclerosis	0.00201	0.00785	CcSEcCtD
Buprenorphine—Osteoarthritis—Riluzole—amyotrophic lateral sclerosis	0.00201	0.00785	CcSEcCtD
Buprenorphine—Disturbance in sexual arousal—Riluzole—amyotrophic lateral sclerosis	0.002	0.00779	CcSEcCtD
Buprenorphine—Migraine—Riluzole—amyotrophic lateral sclerosis	0.00198	0.00773	CcSEcCtD
Buprenorphine—Affect lability—Riluzole—amyotrophic lateral sclerosis	0.00198	0.00773	CcSEcCtD
Buprenorphine—Psychotic disorder—Riluzole—amyotrophic lateral sclerosis	0.00197	0.00767	CcSEcCtD
Buprenorphine—Face oedema—Riluzole—amyotrophic lateral sclerosis	0.00194	0.00758	CcSEcCtD
Buprenorphine—OPRL1—brainstem—amyotrophic lateral sclerosis	0.00193	0.114	CbGeAlD
Buprenorphine—Urinary retention—Riluzole—amyotrophic lateral sclerosis	0.00191	0.00747	CcSEcCtD
Buprenorphine—Mood swings—Riluzole—amyotrophic lateral sclerosis	0.00191	0.00744	CcSEcCtD
Buprenorphine—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.00187	0.0073	CcSEcCtD
Buprenorphine—Orthostatic hypotension—Riluzole—amyotrophic lateral sclerosis	0.00184	0.00717	CcSEcCtD
Buprenorphine—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.00182	0.0071	CcSEcCtD
Buprenorphine—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.00177	0.00693	CcSEcCtD
Buprenorphine—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00177	0.00693	CcSEcCtD
Buprenorphine—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.00175	0.00683	CcSEcCtD
Buprenorphine—Asthma—Riluzole—amyotrophic lateral sclerosis	0.00174	0.00679	CcSEcCtD
Buprenorphine—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.00174	0.00679	CcSEcCtD
Buprenorphine—Influenza—Riluzole—amyotrophic lateral sclerosis	0.00174	0.00679	CcSEcCtD
Buprenorphine—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.00169	0.00661	CcSEcCtD
Buprenorphine—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.00167	0.00653	CcSEcCtD
Buprenorphine—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00167	0.00651	CcSEcCtD
Buprenorphine—OPRM1—nerve—amyotrophic lateral sclerosis	0.00158	0.0936	CbGeAlD
Buprenorphine—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00157	0.00614	CcSEcCtD
Buprenorphine—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00155	0.00605	CcSEcCtD
Buprenorphine—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00155	0.00605	CcSEcCtD
Buprenorphine—Depression—Riluzole—amyotrophic lateral sclerosis	0.00155	0.00603	CcSEcCtD
Buprenorphine—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.00151	0.00588	CcSEcCtD
Buprenorphine—Sweating—Riluzole—amyotrophic lateral sclerosis	0.00149	0.0058	CcSEcCtD
Buprenorphine—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00147	0.00572	CcSEcCtD
Buprenorphine—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.00145	0.00568	CcSEcCtD
Buprenorphine—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.00142	0.00553	CcSEcCtD
Buprenorphine—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.0014	0.00545	CcSEcCtD
Buprenorphine—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.00139	0.00541	CcSEcCtD
Buprenorphine—Hallucination—Riluzole—amyotrophic lateral sclerosis	0.00139	0.00541	CcSEcCtD
Buprenorphine—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.00138	0.00539	CcSEcCtD
Buprenorphine—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00137	0.00537	CcSEcCtD
Buprenorphine—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.00137	0.00535	CcSEcCtD
Buprenorphine—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.00137	0.00534	CcSEcCtD
Buprenorphine—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00136	0.00533	CcSEcCtD
Buprenorphine—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.0013	0.00508	CcSEcCtD
Buprenorphine—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00129	0.00504	CcSEcCtD
Buprenorphine—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00126	0.00493	CcSEcCtD
Buprenorphine—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.00126	0.00491	CcSEcCtD
Buprenorphine—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00125	0.0049	CcSEcCtD
Buprenorphine—Chills—Riluzole—amyotrophic lateral sclerosis	0.00125	0.00487	CcSEcCtD
Buprenorphine—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.00122	0.00476	CcSEcCtD
Buprenorphine—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00121	0.00473	CcSEcCtD
Buprenorphine—OPRL1—spinal cord—amyotrophic lateral sclerosis	0.0012	0.0711	CbGeAlD
Buprenorphine—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.00119	0.00466	CcSEcCtD
Buprenorphine—Tension—Riluzole—amyotrophic lateral sclerosis	0.00119	0.00464	CcSEcCtD
Buprenorphine—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.00119	0.00463	CcSEcCtD
Buprenorphine—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.00118	0.00459	CcSEcCtD
Buprenorphine—Back pain—Riluzole—amyotrophic lateral sclerosis	0.00117	0.00457	CcSEcCtD
Buprenorphine—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.00117	0.00455	CcSEcCtD
Buprenorphine—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00114	0.00443	CcSEcCtD
Buprenorphine—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.00112	0.00439	CcSEcCtD
Buprenorphine—Agitation—Riluzole—amyotrophic lateral sclerosis	0.00111	0.00435	CcSEcCtD
Buprenorphine—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.00111	0.00432	CcSEcCtD
Buprenorphine—Malaise—Riluzole—amyotrophic lateral sclerosis	0.00109	0.00426	CcSEcCtD
Buprenorphine—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.00109	0.00425	CcSEcCtD
Buprenorphine—Syncope—Riluzole—amyotrophic lateral sclerosis	0.00109	0.00424	CcSEcCtD
Buprenorphine—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.00107	0.00418	CcSEcCtD
Buprenorphine—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00107	0.00416	CcSEcCtD
Buprenorphine—Cough—Riluzole—amyotrophic lateral sclerosis	0.00106	0.00413	CcSEcCtD
Buprenorphine—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.00105	0.0041	CcSEcCtD
Buprenorphine—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00408	CcSEcCtD
Buprenorphine—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00403	CcSEcCtD
Buprenorphine—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00403	CcSEcCtD
Buprenorphine—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00403	CcSEcCtD
Buprenorphine—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00401	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00102	0.004	CcSEcCtD
Buprenorphine—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.00102	0.00398	CcSEcCtD
Buprenorphine—OPRL1—nervous system—amyotrophic lateral sclerosis	0.00101	0.0599	CbGeAlD
Buprenorphine—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.00101	0.00394	CcSEcCtD
Buprenorphine—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.000997	0.00389	CcSEcCtD
Buprenorphine—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.000989	0.00386	CcSEcCtD
Buprenorphine—Oedema—Riluzole—amyotrophic lateral sclerosis	0.000989	0.00386	CcSEcCtD
Buprenorphine—Infection—Riluzole—amyotrophic lateral sclerosis	0.000983	0.00383	CcSEcCtD
Buprenorphine—Shock—Riluzole—amyotrophic lateral sclerosis	0.000973	0.0038	CcSEcCtD
Buprenorphine—OPRL1—central nervous system—amyotrophic lateral sclerosis	0.000973	0.0577	CbGeAlD
Buprenorphine—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00097	0.00379	CcSEcCtD
Buprenorphine—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.000965	0.00377	CcSEcCtD
Buprenorphine—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.000961	0.00375	CcSEcCtD
Buprenorphine—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.000956	0.00373	CcSEcCtD
Buprenorphine—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.000943	0.00368	CcSEcCtD
Buprenorphine—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.000924	0.00361	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.000901	0.00352	CcSEcCtD
Buprenorphine—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.000895	0.00349	CcSEcCtD
Buprenorphine—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.000888	0.00347	CcSEcCtD
Buprenorphine—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.000882	0.00344	CcSEcCtD
Buprenorphine—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.000879	0.00343	CcSEcCtD
Buprenorphine—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.000871	0.0034	CcSEcCtD
Buprenorphine—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.00086	0.00336	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000854	0.00333	CcSEcCtD
Buprenorphine—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.000853	0.00333	CcSEcCtD
Buprenorphine—Constipation—Riluzole—amyotrophic lateral sclerosis	0.000846	0.0033	CcSEcCtD
Buprenorphine—Pain—Riluzole—amyotrophic lateral sclerosis	0.000846	0.0033	CcSEcCtD
Buprenorphine—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.000815	0.00318	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.000809	0.00316	CcSEcCtD
Buprenorphine—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.000786	0.00307	CcSEcCtD
Buprenorphine—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.000782	0.00305	CcSEcCtD
Buprenorphine—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.000782	0.00305	CcSEcCtD
Buprenorphine—OPRL1—brain—amyotrophic lateral sclerosis	0.000772	0.0458	CbGeAlD
Buprenorphine—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.000729	0.00284	CcSEcCtD
Buprenorphine—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00071	0.00277	CcSEcCtD
Buprenorphine—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.0007	0.00273	CcSEcCtD
Buprenorphine—OPRM1—brainstem—amyotrophic lateral sclerosis	0.000677	0.0402	CbGeAlD
Buprenorphine—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000677	0.00264	CcSEcCtD
Buprenorphine—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000654	0.00255	CcSEcCtD
Buprenorphine—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000629	0.00245	CcSEcCtD
Buprenorphine—Rash—Riluzole—amyotrophic lateral sclerosis	0.000624	0.00243	CcSEcCtD
Buprenorphine—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000623	0.00243	CcSEcCtD
Buprenorphine—Headache—Riluzole—amyotrophic lateral sclerosis	0.00062	0.00242	CcSEcCtD
Buprenorphine—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000587	0.00229	CcSEcCtD
Buprenorphine—OPRD1—nervous system—amyotrophic lateral sclerosis	0.00052	0.0309	CbGeAlD
Buprenorphine—OPRD1—central nervous system—amyotrophic lateral sclerosis	0.000501	0.0297	CbGeAlD
Buprenorphine—OPRK1—nervous system—amyotrophic lateral sclerosis	0.000499	0.0296	CbGeAlD
Buprenorphine—OPRK1—central nervous system—amyotrophic lateral sclerosis	0.00048	0.0285	CbGeAlD
Buprenorphine—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.000474	0.0281	CbGeAlD
Buprenorphine—OPRK1—cerebellum—amyotrophic lateral sclerosis	0.000469	0.0278	CbGeAlD
Buprenorphine—OPRM1—spinal cord—amyotrophic lateral sclerosis	0.000421	0.025	CbGeAlD
Buprenorphine—OPRD1—brain—amyotrophic lateral sclerosis	0.000398	0.0236	CbGeAlD
Buprenorphine—OPRK1—brain—amyotrophic lateral sclerosis	0.000381	0.0226	CbGeAlD
Buprenorphine—CYP2A6—cerebellum—amyotrophic lateral sclerosis	0.000358	0.0212	CbGeAlD
Buprenorphine—OPRM1—nervous system—amyotrophic lateral sclerosis	0.000355	0.021	CbGeAlD
Buprenorphine—OPRM1—central nervous system—amyotrophic lateral sclerosis	0.000342	0.0203	CbGeAlD
Buprenorphine—CYP2A6—brain—amyotrophic lateral sclerosis	0.000291	0.0172	CbGeAlD
Buprenorphine—ABCG2—medulla oblongata—amyotrophic lateral sclerosis	0.000276	0.0164	CbGeAlD
Buprenorphine—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.000272	0.0161	CbGeAlD
Buprenorphine—OPRM1—brain—amyotrophic lateral sclerosis	0.000271	0.0161	CbGeAlD
Buprenorphine—ABCG2—spinal cord—amyotrophic lateral sclerosis	0.000246	0.0146	CbGeAlD
Buprenorphine—ABCB1—embryo—amyotrophic lateral sclerosis	0.000213	0.0126	CbGeAlD
Buprenorphine—ABCG2—cerebellum—amyotrophic lateral sclerosis	0.000195	0.0116	CbGeAlD
Buprenorphine—CYP2C8—brain—amyotrophic lateral sclerosis	0.000163	0.00968	CbGeAlD
Buprenorphine—ABCG2—brain—amyotrophic lateral sclerosis	0.000159	0.00941	CbGeAlD
Buprenorphine—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.000145	0.00858	CbGeAlD
Buprenorphine—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.000142	0.00844	CbGeAlD
Buprenorphine—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000139	0.00826	CbGeAlD
Buprenorphine—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.000137	0.00812	CbGeAlD
Buprenorphine—ABCB1—medulla oblongata—amyotrophic lateral sclerosis	0.000136	0.00808	CbGeAlD
Buprenorphine—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.000134	0.00794	CbGeAlD
Buprenorphine—ABCB1—spinal cord—amyotrophic lateral sclerosis	0.000121	0.0072	CbGeAlD
Buprenorphine—CYP2D6—brain—amyotrophic lateral sclerosis	0.000109	0.00645	CbGeAlD
Buprenorphine—ABCB1—nervous system—amyotrophic lateral sclerosis	0.000102	0.00607	CbGeAlD
Buprenorphine—ABCB1—central nervous system—amyotrophic lateral sclerosis	9.85e-05	0.00584	CbGeAlD
Buprenorphine—ABCB1—cerebellum—amyotrophic lateral sclerosis	9.63e-05	0.00571	CbGeAlD
Buprenorphine—ABCB1—brain—amyotrophic lateral sclerosis	7.82e-05	0.00464	CbGeAlD
Buprenorphine—OPRL1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.75e-05	0.00133	CbGpPWpGaD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	1.74e-05	0.00132	CbGpPWpGaD
Buprenorphine—CYP2C9—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	1.74e-05	0.00131	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—DAO—amyotrophic lateral sclerosis	1.73e-05	0.00131	CbGpPWpGaD
Buprenorphine—CYP2D6—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	1.73e-05	0.00131	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—VAPA—amyotrophic lateral sclerosis	1.73e-05	0.00131	CbGpPWpGaD
Buprenorphine—CYP2C9—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	1.71e-05	0.0013	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PLB1—amyotrophic lateral sclerosis	1.7e-05	0.00129	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	1.67e-05	0.00127	CbGpPWpGaD
Buprenorphine—ABCB1—Allograft Rejection—CASP3—amyotrophic lateral sclerosis	1.67e-05	0.00126	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	1.65e-05	0.00125	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.65e-05	0.00125	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	1.65e-05	0.00125	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	1.64e-05	0.00124	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—VAPB—amyotrophic lateral sclerosis	1.64e-05	0.00124	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—TPK1—amyotrophic lateral sclerosis	1.64e-05	0.00124	CbGpPWpGaD
Buprenorphine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—amyotrophic lateral sclerosis	1.63e-05	0.00124	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—CHAT—amyotrophic lateral sclerosis	1.63e-05	0.00124	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	1.62e-05	0.00123	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.61e-05	0.00122	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	1.57e-05	0.00119	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—GSR—amyotrophic lateral sclerosis	1.57e-05	0.00119	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	1.55e-05	0.00117	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	1.53e-05	0.00115	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—C3—amyotrophic lateral sclerosis	1.52e-05	0.00115	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—FIG4—amyotrophic lateral sclerosis	1.51e-05	0.00114	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—VAPA—amyotrophic lateral sclerosis	1.5e-05	0.00113	CbGpPWpGaD
Buprenorphine—ABCB1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	1.49e-05	0.00112	CbGpPWpGaD
Buprenorphine—CYP1A2—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	1.49e-05	0.00112	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	1.47e-05	0.00111	CbGpPWpGaD
Buprenorphine—CYP1A2—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	1.46e-05	0.00111	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—VAPB—amyotrophic lateral sclerosis	1.46e-05	0.00111	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—TPK1—amyotrophic lateral sclerosis	1.46e-05	0.00111	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.46e-05	0.0011	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PLB1—amyotrophic lateral sclerosis	1.44e-05	0.00109	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	1.44e-05	0.00109	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PLB1—amyotrophic lateral sclerosis	1.43e-05	0.00108	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.43e-05	0.00108	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—VAPB—amyotrophic lateral sclerosis	1.43e-05	0.00108	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—TPK1—amyotrophic lateral sclerosis	1.43e-05	0.00108	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	1.42e-05	0.00108	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	1.42e-05	0.00108	CbGpPWpGaD
Buprenorphine—ABCB1—Allograft Rejection—VEGFA—amyotrophic lateral sclerosis	1.41e-05	0.00107	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	1.4e-05	0.00106	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	1.39e-05	0.00105	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.39e-05	0.00105	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—DAO—amyotrophic lateral sclerosis	1.37e-05	0.00103	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	1.36e-05	0.00103	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.36e-05	0.00103	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—TPK1—amyotrophic lateral sclerosis	1.34e-05	0.00102	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—VAPB—amyotrophic lateral sclerosis	1.34e-05	0.00102	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—VAPA—amyotrophic lateral sclerosis	1.34e-05	0.00101	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—GSR—amyotrophic lateral sclerosis	1.33e-05	0.00101	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—VAPB—amyotrophic lateral sclerosis	1.33e-05	0.00101	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—TPK1—amyotrophic lateral sclerosis	1.33e-05	0.00101	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—GSR—amyotrophic lateral sclerosis	1.32e-05	0.001	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PLB1—amyotrophic lateral sclerosis	1.31e-05	0.000993	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	1.31e-05	0.00099	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—FIG4—amyotrophic lateral sclerosis	1.31e-05	0.00099	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—VAPA—amyotrophic lateral sclerosis	1.3e-05	0.000986	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—CHAT—amyotrophic lateral sclerosis	1.29e-05	0.000976	CbGpPWpGaD
Buprenorphine—ABCB1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	1.26e-05	0.000956	CbGpPWpGaD
Buprenorphine—ABCB1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	1.26e-05	0.000956	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	1.26e-05	0.000955	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	1.25e-05	0.000945	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.24e-05	0.00094	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	1.24e-05	0.000939	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	1.24e-05	0.000939	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—VAPA—amyotrophic lateral sclerosis	1.23e-05	0.00093	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—VAPA—amyotrophic lateral sclerosis	1.22e-05	0.000922	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.21e-05	0.000917	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—GSR—amyotrophic lateral sclerosis	1.21e-05	0.000916	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	1.2e-05	0.000909	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	1.19e-05	0.000901	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—DAO—amyotrophic lateral sclerosis	1.18e-05	0.000895	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.18e-05	0.000891	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—FIG4—amyotrophic lateral sclerosis	1.17e-05	0.000883	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	1.16e-05	0.000876	CbGpPWpGaD
Buprenorphine—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	1.15e-05	0.000867	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.14e-05	0.000864	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—FIG4—amyotrophic lateral sclerosis	1.14e-05	0.000862	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—VAPB—amyotrophic lateral sclerosis	1.14e-05	0.000861	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—TPK1—amyotrophic lateral sclerosis	1.14e-05	0.000861	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.13e-05	0.000857	CbGpPWpGaD
Buprenorphine—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	1.13e-05	0.000855	CbGpPWpGaD
Buprenorphine—ABCB1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	1.13e-05	0.000852	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.12e-05	0.000847	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—CHAT—amyotrophic lateral sclerosis	1.1e-05	0.000828	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—CHAT—amyotrophic lateral sclerosis	1.09e-05	0.000821	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—FIG4—amyotrophic lateral sclerosis	1.07e-05	0.000813	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	1.07e-05	0.000809	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	1.07e-05	0.000807	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—FIG4—amyotrophic lateral sclerosis	1.06e-05	0.000805	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	1.06e-05	0.000803	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—DAO—amyotrophic lateral sclerosis	1.06e-05	0.000799	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	1.06e-05	0.000798	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	1.05e-05	0.000796	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	1.04e-05	0.00079	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—VAPA—amyotrophic lateral sclerosis	1.04e-05	0.000787	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PLB1—amyotrophic lateral sclerosis	1.04e-05	0.000783	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—DAO—amyotrophic lateral sclerosis	1.03e-05	0.00078	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	1.02e-05	0.000769	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—CHAT—amyotrophic lateral sclerosis	9.95e-06	0.000753	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	9.78e-06	0.00074	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	9.71e-06	0.000735	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—SACM1L—amyotrophic lateral sclerosis	9.68e-06	0.000732	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—DAO—amyotrophic lateral sclerosis	9.63e-06	0.000728	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—GSR—amyotrophic lateral sclerosis	9.55e-06	0.000723	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	9.23e-06	0.000698	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	9.18e-06	0.000694	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—FIG4—amyotrophic lateral sclerosis	9.1e-06	0.000688	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PLB1—amyotrophic lateral sclerosis	8.97e-06	0.000678	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	8.86e-06	0.000671	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	8.82e-06	0.000667	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	8.78e-06	0.000664	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	8.78e-06	0.000664	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—GSTP1—amyotrophic lateral sclerosis	8.77e-06	0.000664	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	8.74e-06	0.000661	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	8.62e-06	0.000652	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	8.59e-06	0.00065	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	8.58e-06	0.000649	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—GSR—amyotrophic lateral sclerosis	8.28e-06	0.000626	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—DAO—amyotrophic lateral sclerosis	8.23e-06	0.000622	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	8.23e-06	0.000622	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	8.15e-06	0.000616	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	8.07e-06	0.00061	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	8.06e-06	0.00061	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	8.05e-06	0.000609	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	8.03e-06	0.000608	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PLB1—amyotrophic lateral sclerosis	8e-06	0.000605	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—CHAT—amyotrophic lateral sclerosis	7.85e-06	0.000594	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	7.81e-06	0.000591	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	7.8e-06	0.00059	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	7.66e-06	0.00058	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	7.54e-06	0.00057	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	7.48e-06	0.000566	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	7.47e-06	0.000565	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—GSR—amyotrophic lateral sclerosis	7.39e-06	0.000559	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	7.36e-06	0.000557	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	7.32e-06	0.000553	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PLB1—amyotrophic lateral sclerosis	7.3e-06	0.000552	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	7.25e-06	0.000548	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	7.21e-06	0.000545	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	7.03e-06	0.000532	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	7.02e-06	0.000531	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	6.98e-06	0.000528	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—GSTP1—amyotrophic lateral sclerosis	6.94e-06	0.000525	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	6.8e-06	0.000514	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—CHAT—amyotrophic lateral sclerosis	6.8e-06	0.000514	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	6.79e-06	0.000514	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—GSR—amyotrophic lateral sclerosis	6.73e-06	0.000509	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	6.73e-06	0.000509	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—APOE—amyotrophic lateral sclerosis	6.63e-06	0.000502	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	6.56e-06	0.000496	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	6.48e-06	0.00049	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.37e-06	0.000482	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	6.35e-06	0.00048	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PLB1—amyotrophic lateral sclerosis	6.24e-06	0.000472	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—C3—amyotrophic lateral sclerosis	6.22e-06	0.00047	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	6.2e-06	0.000469	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	6.17e-06	0.000466	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	6.13e-06	0.000464	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CHAT—amyotrophic lateral sclerosis	6.07e-06	0.000459	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	5.92e-06	0.000448	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—GSTP1—amyotrophic lateral sclerosis	5.89e-06	0.000445	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—GSTP1—amyotrophic lateral sclerosis	5.83e-06	0.000441	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	5.79e-06	0.000438	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GSR—amyotrophic lateral sclerosis	5.76e-06	0.000435	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	5.58e-06	0.000422	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	5.54e-06	0.000419	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	5.53e-06	0.000419	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CHAT—amyotrophic lateral sclerosis	5.53e-06	0.000418	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	5.53e-06	0.000418	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—C3—amyotrophic lateral sclerosis	5.45e-06	0.000412	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	5.41e-06	0.000409	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	5.36e-06	0.000406	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—GSTP1—amyotrophic lateral sclerosis	5.35e-06	0.000404	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	5.28e-06	0.000399	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—APOE—amyotrophic lateral sclerosis	5.24e-06	0.000397	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	5.24e-06	0.000396	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	5.21e-06	0.000394	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	5.07e-06	0.000384	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	5.05e-06	0.000382	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.91e-06	0.000372	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	4.81e-06	0.000364	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	4.78e-06	0.000362	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CHAT—amyotrophic lateral sclerosis	4.73e-06	0.000358	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—C3—amyotrophic lateral sclerosis	4.61e-06	0.000348	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.55e-06	0.000344	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—APOE—amyotrophic lateral sclerosis	4.45e-06	0.000337	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	4.44e-06	0.000336	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—APOE—amyotrophic lateral sclerosis	4.41e-06	0.000334	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	4.31e-06	0.000326	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	4.29e-06	0.000324	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	4.25e-06	0.000321	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.22e-06	0.000319	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	4.19e-06	0.000317	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—APOE—amyotrophic lateral sclerosis	4.04e-06	0.000306	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.87e-06	0.000293	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	3.79e-06	0.000287	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.68e-06	0.000278	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.65e-06	0.000276	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	3.65e-06	0.000276	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.59e-06	0.000272	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	3.54e-06	0.000268	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.48e-06	0.000263	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	3.46e-06	0.000262	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.36e-06	0.000254	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.26e-06	0.000247	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.23e-06	0.000244	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—APOE—amyotrophic lateral sclerosis	3.19e-06	0.000241	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.18e-06	0.000241	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.12e-06	0.000236	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.05e-06	0.000231	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.05e-06	0.000231	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.02e-06	0.000229	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	3e-06	0.000227	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3e-06	0.000227	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.97e-06	0.000225	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	2.95e-06	0.000224	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.92e-06	0.000221	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.77e-06	0.00021	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—APOE—amyotrophic lateral sclerosis	2.76e-06	0.000209	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.76e-06	0.000208	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.74e-06	0.000207	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.73e-06	0.000207	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.73e-06	0.000206	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.58e-06	0.000195	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.54e-06	0.000192	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—APOE—amyotrophic lateral sclerosis	2.46e-06	0.000186	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	2.41e-06	0.000182	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.36e-06	0.000179	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.33e-06	0.000177	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.31e-06	0.000175	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	2.27e-06	0.000171	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—APOE—amyotrophic lateral sclerosis	2.25e-06	0.00017	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.18e-06	0.000165	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.07e-06	0.000157	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.96e-06	0.000148	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—APOE—amyotrophic lateral sclerosis	1.92e-06	0.000145	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.89e-06	0.000143	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.8e-06	0.000136	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.75e-06	0.000132	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.69e-06	0.000128	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.65e-06	0.000125	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.55e-06	0.000118	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.54e-06	0.000116	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	1.48e-06	0.000112	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.32e-06	9.95e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.02e-06	7.68e-05	CbGpPWpGaD
